Developing as a promising development in the battle against obesity, this medication is generating considerable interest . It combines properties of two known GLP-1 receptor agonists, liraglutide, plus an unique glucose-dependent incretin component. Initial clinical data have shown substantial fat reduction in patients with a high BMI , perhaps pr